Search > Eye Redness
My employer runs this trial

Apraclonidine for Eye Redness

AC
Overseen ByAlcon Call Center
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: Alcon Research
Disqualifiers: Ocular surgery, Pregnancy, Breastfeeding, others
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this study is to evaluate the efficacy and safety of an investigational ophthalmic solution in adults with ocular redness due to minor eye irritations.

Who Is on the Research Team?

CT

Clinical Trial Lead, Pharma

Principal Investigator

Alcon Research, LLC

Are You a Good Fit for This Trial?

Inclusion Criteria

My eye health is stable.
Best corrected visual acuity at distance of 0.3 logarithm Minimum Angle of Resolution or better in each eye
Other protocol-defined inclusion criteria may apply
See 4 more

Exclusion Criteria

I have had eye surgery in the past 6 months or plan to have it during the study.
Known contraindications or sensitivity to the use of any of the study treatment(s) or their components, or any other medication required by the protocol
Ocular conditions that, in the opinion of the investigator, could affect the subject's safety or study parameters
See 4 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

1 week
1 visit (in-person)

Treatment

Participants receive a single dose of the study treatment in each eye on Day 1

1 day
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

1 week
1 visit (in-person)

What Are the Treatments Tested in This Trial?

Interventions

  • Apraclonidine Ophthalmic Solution

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Placebo Group

Group I: Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative FreeExperimental Treatment1 Intervention
Group II: VehiclePlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Alcon Research

Lead Sponsor

Trials
739
Recruited
128,000+
Raquel C. Bono profile image

Raquel C. Bono

Alcon Research

Chief Medical Officer since 2022

MD from Harvard Medical School

David Endicott profile image

David Endicott

Alcon Research

Chief Executive Officer since 2018

MBA from University of Southern California

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.